美国政府停摆结束！黄金、创新药联袂上攻，恒生医药ETF、黄金股ETF涨超3%，10连“吸金”黄金ETF华夏涨1.4%

Group 1 - The gold and innovative drug sectors continue to rise, with the gold ETF Huaxia increasing by 1.41% and the more elastic gold stock ETF rising by 3.12%, while the Hang Seng Pharmaceutical ETF gained 3.36%, marking two consecutive days of gains [1] - Spot gold rebounded to $4,196.54 per ounce, aiming for the $4,200 mark, following the signing of a federal government temporary funding bill by President Trump, which ended a 43-day government shutdown, improving dollar liquidity and boosting both risk and safe-haven assets [2] - BeiGene's stock surged over 6%, reaching a four-year high, with Q3 revenue of 10.077 billion yuan, a year-on-year increase of 41.1%, and both Q3 and year-to-date net profits turning positive [2] Group 2 - The gold ETF Huaxia (518850) tracks the SGE Gold 9999 Index with a total fee rate of 0.2%, the lowest in its category, while the gold stock ETF (159562) tracks SSH gold stocks, primarily consisting of gold and copper, with a similar fee rate [2] - The Hang Seng Pharmaceutical ETF (159892) represents the global pharmaceutical industry chain with a latest scale of 6.15 billion yuan, featuring top-weighted stocks including BeiGene, WuXi Biologics, and others [3] - Recent inflows into gold ETFs have been significant, with a net inflow of 1.26 billion yuan in a single day, and the Huaxia gold ETF attracting net inflows for 10 consecutive days, totaling 2.015 billion yuan over the past 20 days [2]